Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
Zacks
More News
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.
Zacks
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
FTRE vs. ARGX: Which Stock Is the Better Value Option?
FTRE vs. ARGX: Which Stock Is the Better Value Option?
Zacks
Best Momentum Stock to Buy for July 31st
FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.
Zacks
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum
Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +27.78% and +4.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc.(FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm
Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (Fortrea) on behalf of the companys long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed...
Business Wire
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.